Molecular Vaccines : From Prophylaxis to Therapy - Volume 2 / edited by Matthias Giese.

Por:

Giese, Matthias [editor.]

Colaborador(es):

SpringerLink (Servicio en línea)

Tipo de material: Texto

TextoEditor: Cham : Springer International Publishing : Imprint: Springer, 2014Descripción: xxviii, 870 páginas 98 ilustraciones, 74 ilustraciones en color. recurso en líneaTipo de contenido:

texto

Tipo de medio:

computadora

Tipo de portador:

recurso en línea

ISBN:

9783319009780

Formatos físicos adicionales: Edición impresa:: Sin títuloClasificación LoC:

RM281

Recursos en línea:

Conectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)

Contenidos:

Non-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.

Resumen: This title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.

Existencias ( 0 )
Notas de título ( 4 )

No hay ítems correspondientes a este registro

Springer eBooks

Non-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.

This title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.

Para consulta fuera de la UANL se requiere clave de acceso remoto.